ICOTYDE (icotrokinra)
FDA approved March 18, 2026 for plaque psoriasis; EU approved September 21, 2026.
What it is
First oral peptide that blocks the IL-23 receptor, taken once daily, for moderate-to-severe plaque psoriasis. Discovered with Protagonist Therapeutics. The company is positioning it as a first-line systemic treatment that competes with biologic and oral psoriasis drugs.
Why it matters to the stock. Its launch is J&J's main answer to STELARA erosion in immunology, so early uptake matters for the 2027 growth outlook.
News
ICOTYDE two-year ICONIC-TOTAL data show 70% clear or almost clear skin
J&J presented two-year Phase 3 ICONIC-TOTAL data for ICOTYDE at the EADV Congress 2026 as a late-breaking oral presentation.
European Commission approves ICOTYDE for moderate-to-severe plaque psoriasis
The European Commission granted marketing authorisation to ICOTYDE (icotrokinra), an oral IL-23 receptor blocker, for adults and adolescents aged 12 and older weighing at least 40 kg who are candidates for systemic therapy.
FDA approves ICOTYDE, first oral IL-23 receptor peptide, for plaque psoriasis
The FDA approved ICOTYDE (icotrokinra), a once-daily oral peptide that blocks the IL-23 receptor, for moderate-to-severe plaque psoriasis in adults and patients aged 12 and older weighing at least 40 kg.